Bronchial Asthma Clinical Trial
Official title:
The Rationale of Applying Inspiratory/Expiratory Muscle Training Within the Same Respiratory Cycle in Children With Bronchial Asthma: A Placebo-controlled Randomized Clinical Trial
Verified date | January 2022 |
Source | Cairo University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study was designed to assess the effect of inspiratory and expiratory muscle training in the same cycle on respiratory muscle strength, pulmonary functions, perception of asthma symptoms in children with bronchial asthma. Fifty-one children with bronchial asthma were randomly allocated to the unloaded respiratory muscle training (Placebo training group; n = 17), inspiratory muscle training alone (inspiratory muscle training group; n = 17), or combined inspiratory and expiratory muscle training in the same cycle (combined training group; n = 17). All groups were assessed for respiratory muscle strength, pulmonary functions, and asthma symptoms.
Status | Completed |
Enrollment | 51 |
Est. completion date | October 28, 2021 |
Est. primary completion date | October 28, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 18 Years |
Eligibility | Inclusion Criteria: - Confirmed diagnosis of asthma according to Global Initiative of Asthma guidelines. - Age between 12 and 18 years. - Clinically stable asthma. - Stable doses of medications in the last three months - A percent-predicted value of the peak expiratory flow rate of 60-80% - No activity limitation due to asthma Exclusion Criteria: - Unstable asthma - Exacerbation of asthma symptoms - History of thoracic surgery - Cognitive/behavioral problems - Cardiopulmonary co-morbidities |
Country | Name | City | State |
---|---|---|---|
Saudi Arabia | Ragab K. Elnaggar | Al Kharj | Riyadh |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Saudi Arabia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Inspiratory muscle strength | Inspiratory muscle strength was assessed by measuring the maximal inspiratory pressure (reflects the strength of the diaphragm and other inspiratory muscles) using an electronic respiratory pressure meter, according to the American Thoracic Society and European Respiratory Society standards. The highest value of three acceptable trials was documented and used for the subsequent analysis. The percent predicted maximal inspiratory pressure values (%) were calculated and used for statistical analysis. | 2 months | |
Primary | Expiratory muscle strength | Expiratory muscle strength was assessed by measuring the maximal expiratory pressure (reflects the strength of the abdominal muscles and other expiratory muscles) using an electronic respiratory pressure meter, according to the American Thoracic Society and European Respiratory Society standards. The highest value of three acceptable trials was documented and used for the subsequent analysis. The percent predicted maximal inspiratory pressure values (%) were calculated and used for statistical analysis. | 2 months | |
Primary | Forced vital capacity | Forced vital capacity, which is the amount of air that each participant was able to forcibly exhale from his/her lungs after taking the deepest breath they can, was measured in a pulmonary function test with a spirometry analyzer and expressed as a percentage of predicted values (%). Three trials were allowed and the best results were recorded. | 2 months | |
Primary | Forced expiratory volume in one second | Forced expiratory volume in one second, which is the volume of air exhaled in the first second during forced exhalation after a maximal inspiration, was measured in a pulmonary function test with a spirometry analyzer and expressed as a percentage of predicted values (%). Three trials were allowed and the best results were recorded. | 2 months | |
Primary | Forced expiratory volume in one second / forced vital capacity | Forced expiratory volume in one second / forced vital capacity, is the ratio of the forced expiratory volume in the first one second to the forced vital capacity of the lungs. | 2 months | |
Secondary | Asthma symptoms | A translated version of the asthma control test was used to assess the degree of control over asthma symptoms. The test is patient-administered consists of 5 items. Each item has five possible responses (1: not controlled and 5: completely controlled). the test score ranges from 5 (inadequate control) to 25 (optimal control). | 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02934945 -
Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients
|
Phase 4 | |
Completed |
NCT02561351 -
Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation
|
N/A | |
Recruiting |
NCT01759472 -
Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test
|
N/A | |
Completed |
NCT01918293 -
Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult
|
N/A | |
Completed |
NCT01203904 -
Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation
|
N/A | |
Completed |
NCT01762917 -
Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing
|
N/A | |
Completed |
NCT00536731 -
Symbicort Rapihaler Therapeutic Equivalence Study
|
Phase 3 | |
Completed |
NCT00331929 -
Respiratory Health Study of Children in Kiryat Tivon
|
N/A | |
Completed |
NCT00930826 -
Childhood Asthma and Schooling: The Truth Unveiled
|
N/A | |
Completed |
NCT00327028 -
Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma
|
Phase 4 | |
Completed |
NCT00413387 -
Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)
|
Phase 3 | |
Completed |
NCT00950794 -
Study of Salmeterol (SN408D) for Adult Asthma
|
Phase 4 | |
Completed |
NCT00153283 -
Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma
|
Phase 4 | |
Completed |
NCT00142025 -
Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma
|
Phase 4 | |
Completed |
NCT00153270 -
Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma
|
Phase 4 | |
Completed |
NCT03450434 -
XC8 in the Treatment of Patients With Bronchial Asthma
|
Phase 2 | |
Recruiting |
NCT05189613 -
Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis
|
N/A | |
Recruiting |
NCT04128111 -
Study on the Correlation Between TCM Syndrome, Inflammatory Phenotype and Biomarker of Bronchial Asthma
|
||
Completed |
NCT06326632 -
Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma
|
N/A | |
Completed |
NCT05088512 -
The Role of Genetic Factors in the Development of Bronchial Asthma in the Kazakh Population
|